Tuesday, December 2, 2025 -Falcon 9 — Global health experts are sounding the alarm: fewer than 1 in 10 people who could benefit from obesity-fighting injections can actually access them, according to new WHO guidance.
The drugs — known as GLP-1 therapies, often referred to as “obesity jabs” or “skinny jabs” — have recently been added to WHO’s list of essential medicines and are now conditionally recommended for long-term use in adults struggling with obesity.
But despite their potential, access remains severely constrained. Limited manufacturing capacity, high prices, and supply-chain bottlenecks mean that even under optimistic forecasts, these treatments may reach less than 10% of people worldwide who need them by 2030.
This shortfall comes as global health officials warn that obesity rates could double by 2030 if meaningful action isn’t taken. The gap between soaring demand and limited supply is widening, raising concerns among health authorities that millions are being left behind.
WHO warns that this shortage risks deepening global health inequalities and urges urgent action to expand production, improve affordability, and ensure global access. The organization also stresses that medication alone cannot reverse the global obesity crisis.
Effective progress requires a combination of supportive public health environments, healthier diets, and increased physical activity — with GLP-1 medicines positioned as just one part of a much broader strategy.
0 Comments